FOX-04-DRI is a senolytic peptide that selectively forces senescent (zombie) cells into apoptosis without harming healthy tissue — making it one of the most targeted anti-aging research tools available.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Senescent cells are damaged cells that stop dividing but refuse to die. They accumulate with age and release a toxic cocktail of inflammatory signals (the SASP — Senescence-Associated Secretory Phenotype) that damages surrounding tissue, drives chronic inflammation, and accelerates aging in nearby cells. FOX-04-DRI is a synthetic retro-inverso peptide designed to disrupt the molecular mechanism that keeps senescent cells alive. In preclinical research, clearing senescent cells extended healthy lifespan and reversed physical decline in aged mice.
Mechanism of Action
Senescent cells survive by hijacking the FOXO4 transcription factor to sequester p53 — the protein that would otherwise trigger cell death — in the nucleus. FOX-04-DRI is a modified peptide that competes with this interaction, displacing FOXO4 from p53 and allowing p53 to initiate apoptosis specifically in senescent cells. Healthy cells, which do not rely on this FOXO4-p53 survival mechanism, are unaffected. The retro-inverso modification (D-amino acids in reverse sequence) makes the peptide resistant to enzymatic degradation and able to cross cell membranes.
Key Research
Published in Nature in 2017 by Baar et al. (van Deursen lab, Mayo Clinic), FOX-04-DRI eliminated senescent cells from aged mice, improved physical fitness, restored fur density, and extended median healthy lifespan. The paper demonstrated that clearing FOXO4-p53-dependent senescent cells — without harming healthy tissue — reversed multiple hallmarks of physical aging. No human clinical trials have been conducted. The compound is a research tool; clinical senolytics (navitoclax, dasatinib + quercetin) are in separate trial programs.
1–2 mg subcutaneously, 3 consecutive days per month
Half-Life
~2–4 hours
Typical research protocols use a short pulse approach: 1–2 mg subcutaneously for 3 consecutive days, then 4 weeks off before repeating. Some protocols extend to once monthly. Because senescent cell burden is relatively stable on a monthly timescale, continuous daily dosing is not necessary — and pulsing avoids excessive apoptotic load. Doses should be prepared fresh from lyophilized powder. No standard clinical dose has been established for humans.
Senolytic Pulse Protocol: 1.5 mg subcutaneously daily for 3 consecutive days, repeated once monthly for 3–6 months. Often combined with Epithalon or GHK-Cu as part of a longevity-focused protocol targeting both cellular senescence and telomere maintenance.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Injection site discomfort and mild redness are the most commonly reported effects. Transient fatigue following dosing has been noted in some research subjects, possibly reflecting the apoptotic clearance process. Because the peptide induces targeted cell death, individuals with high senescent cell burden may experience a temporary inflammatory response as those cells are cleared — sometimes described as a brief flu-like feeling. No endocrine suppression or organ toxicity has been identified in preclinical models.
Storage & Handling
Store lyophilized powder at -20°C (freezer) for long-term storage. At 2–8°C, stable for up to 3 months. Once reconstituted with bacteriostatic water, use within 14–21 days and keep refrigerated. Protect from light. FOX-04-DRI is moderately fragile in solution — avoid repeated freeze-thaw cycles.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
